Mide Kanserinde Kullanılan Biyobelirteçler ve CA 72-4

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.

Matsuzaki J, Tsugawa H, Suzuki H. Precision Medicine Approaches to Prevent Gastric Cancer. Gut Liver. 2021 Jan;15(1):3-12.

O'Connor A, O'Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):230-240.

Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020 Dec;69(12):2113-2121.

Grady WM, Yu M, Markowitz SD. Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. Gastroenterology. 2021 Feb;160(3):690-709.

Yu J, Zhang S, Zhao B. Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer. Mol Clin Oncol. 2016 Mar;4(3):441-449.

Gold P, Freedman So. Demonstratıon of tumor-specıfıc antıgens ın human colonıc carcınomata by ımmunologıcal tolerance and absorptıon technıques. J Exp Med. 1965 Mar 1;121(3):439-62.

Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, et al. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. J Cancer. 2018 Jan 1;9(3):494-501.

Lin JK, Lin CC, Yang SH, Wang HS, Jiang JK, Lan YT, et al. Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. Int J Colorectal Dis. 2011 Sep;26(9):1135-41.

Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979 Nov;5(6):957-71.

Jing JX, Wang Y, Xu XQ, Sun T, Tian BG, Du LL, et al. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Asian Pac J Cancer Prev. 2014;15(23):10267-72.

Gasparri F, Wang N, Skog S, Galvani A, Eriksson S. Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. Eur J Cell Biol. 2009 Dec;88(12):779-85.

Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem. 2010 Aug 27;285(35):27327-27335.

Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, et al. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. J Cancer. 2018 Jan 1;9(3):494-501.

Chen G, He C, Li L, Lin A, Zheng X, He E, et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix. BMC Cancer. 2013 May 21;13:249.

Nisman B, Nechushtan H, Biran H, Gantz-Sorotsky H, Peled N, Gronowitz S, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. J Thorac Oncol. 2014 Oct;9(10):1568-72.

Chen Z, Zhou H, Li S, He E, Hu J, Zhou J, et al. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Res. 2008 Nov-Dec;28(6B):3897-907.

Liu Y, Ling Y, Qi Q, Tang Y, Xu J, Tong Z, et al. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med. 2011 Nov;2(6):1177-1181.

Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1247 cancer patients in routine clinical settings. Int J Clin Oncol. 2010 Aug;15(4):359-68.

Wu XS, Xi HQ, Chen L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol. 2012 Nov 15;10:244.

Roșu MC, Ardelean A, Moldovan SD, Faur FI, Nesiu A, Totoloci BD. The importance of CA 72-4 and CA 19-9 dosing in gastric cancer. J Med Life. 2023 Feb;16(2):186-188.

Cho J, Kim KM, Kim HC, Lee WY, Kang WK, Park YS, et al. The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. Pathol Res Pract. 2019 Jan;215(1):171-176.

Li M, Men X, Zhang X. Diagnostic value of carbohydrate antigen 72-4 combined with carbohydrate antigen 15.3 in ovarian cancer, cervical cancer and endometrial cancer. J BUON. 2020 Jul-Aug;25(4):1918-1927.

Mariampillai AI, Cruz JPD, Suh J, Sivapiragasam A, Nevins K, Hindenburg AA. Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries. Anticancer Res. 2017 Jul;37(7):3649-3656.

Zeimet AG, Guadagni F, Marth C, Amato T, Müller-Holzner E, Huter O, et al. Stellenwert des Tumormarkers TAG-72 (CA 72-4) bei der Primärdiagnostik des Ovarialkarzinoms. Ein Vergleich mit dem etablierten Marker CA-125 [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker]. Geburtshilfe Frauenheilkd. 1995 Apr;55(4):195-9. German.

Schutter EM, Sohn C, Kristen P, Möbus V, Crombach G, Kaufmann M, et al. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol. 1998 Apr;69(1):56-63.

Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, Kimmig R, Zeller T, et al. Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer. Future Sci OA. 2016 Oct 12;2(4):FSO145.

Anastasi E, Manganaro L, Granato T, Benedetti Panici P, Frati L, Porpora MG. Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer? Dis Markers. 2013;35(5):331-5.

Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, et al. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res. 1992 Mar 1;52(5):1222-7.

Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Casaldi V, et al. Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carcinoma. Anticancer Res. 1993 Nov-Dec;13(6B):2409-13.

Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6(3):142-5.

Xu Y, Zhang P, Zhang K, Huang C. The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188634.

Zhang Y, Zhang M, Bai X, Li C, Zhang L. Increased serum CA724 levels in patients suffering gout vs cancers. Prog Mol Biol Transl Sci. 2019;162:177-186.

Jiexian J, Xiaoqin X, Lili D, Baoguo T, Ting S, Xianwen Z, et al. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer. Int J Biol Markers. 2013 Jun 28;28(2):192-200.

Liu X, Cai H, Wang Y. Prognostic significance of tumour markers in Chinese patients with gastric cancer. ANZ J Surg. 2014 Jun;84(6):448-53.

Li F, Li S, Wei L, Liang X, Zhang H, Liu J. The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment. Biomarkers. 2013 Nov;18(7):632-7.

L.Q. Wang, X.L. Cheng, Y.K. Chen. Correlation analysis of serum CEA, CA199 and CA724 with postoperative recurrence and metastasis of gastric cancer. Electron. J. Clin. Gen. Surg., 1 (04) (2013), pp. 48-50

Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 2014 Dec 29;12:397.

Peng W, Zhou Z, Zhong Y, Sun Y, Wang Y, Zhu Z, et al. Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer. Sci Rep. 2019 Dec 13;9(1):19084.

Zou L, Qian J. Decline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinoma. Chin J Cancer Res. 2014 Aug;26(4):404-9.

Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006 May-Jun;26(3B):2237-42.

Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16(3-4):105-10.

Rossin R, Versteegen RM, Wu J, Khasanov A, Wessels HJ, Steenbergen EJ, et al. Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Nat Commun. 2018 May 4;9(1):1484.